No Result
View All Result
  • Private Data
  • Membership options
  • Login
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHubHOT
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Home COUNTRY FRANCE

French BioTech developer SeaBeLife raises €2 million to tackle dry AMD and severe acute hepatitis

EU Startupsby EU Startups
October 1, 2025
Reading Time: 3 mins read
in FRANCE, VENTURE CAPITAL
Share on FacebookShare on Twitter

Roscoff-based SeaBeLife, a BioTech company developing innovative drug candidates intended to block cellular necrosis, today announces a pre-Series A funding round worth €2 million.

The financing was led by historical investor iXLife, alongside other longstanding shareholders Breizh Angels, WeLikeStartup, Angels Santé and the Business Angels des Grandes Ecoles. This round welcomes new investors, including INEXT and Femmes Business Angels, the first women-only business angels’ network in Europe.

“The renewed backing from our longstanding investors, together with the addition of new partners, is a clear signal of confidence in our vision and development strategy, and I am extremely grateful for their support,” said Morgane Rousselot, PhD, CEO and Co-founder of SeaBeLife. “This fundraising is a decisive step towards clinical trials and reinforces our ambition to create a new generation of cutting-edge treatments capable of blocking two major pathways for programmed cell death. We are now actively preparing for a Series A funding round to sustain this momentum.”

Founded in 2019, SeaBeLife focuses on developing novel small molecules that simultaneously target two major regulated cell death pathways, necroptosis and ferroptosis, to meet key medical needs in acute, rare or chronic indications where there is no therapeutic alternative.

This first-in-class approach is reportedly unique, as there is currently no dual inhibitor targeting these pathways available on the market. At the start of 2025, the company delivered promising preclinical efficacy results for its SBL03 drug candidate in geographic atrophy, a severe form of dry AMD.

The company is focusing its efforts on two flagship programmes: SBL03 for dry AMD, and SBL01 for severe acute hepatitis, two high medical need indications for which the potential market is worth several billion euros.

“We have backed SeaBeLife for several years and the latest in vivo data validates the value and potential of the company’s dual-targeted approach. By simultaneously blocking two forms of regulated cell death, SeaBeLife uniquely shields organs from damage, highlighting its transformative potential to provide patients with rare or chronic diseases with a new therapeutic option,” said Jean-Pierre Kinet, chairman of iXLife.

This funding marks a key milestone for SeaBeLife by supporting the development of two of the company’s drug candidates – one aimed at dry age-related macular degeneration (AMD) and the other for severe acute hepatitis. The first clinical trial is set to start in 2026.

Further to this financing round, Marie-Pierre Sbardella, general secretary of Femmes Business Angels, joins the SeaBeLife Strategic Committee.

“We at INEXT are impressed by SeaBeLife’s disruptive technology, which concurrently blocks two regulated cell death pathways, protecting the organs from serious diseases. Its first-in-class approach, which is supported by promising preclinical results, positions SeaBeLife as a key player in the future of biotech. We are proud to have contributed to this fundraising and to support the company’s growth,” said Eric Valat, chairman of INEXT.

Since inception, SeaBeLife has raised €9 million in capital and public financing. It is led by CEO and Co-founder Morgane Rousselot, who holds a PhD in biochemistry from Sorbonne University/French National Center for Scientific Research (CNRS)/Roscoff Marine Station.

The company is based on the research work of Stéphane Bach, PhD (CNRS), Marie-Thérèse Dimanche-Boitrel (Research Institute for Environmental and Occupational Health — IRSET) and Claire Delehouzé, PhD, scientific director and partner.

Read the orginal article: https://www.eu-startups.com/2025/10/french-biotech-developer-seabelife-raises-e2-million-to-tackle-dry-amd-and-severe-acute-hepatitis/

Gateways to Italy

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

Gateways to Italy – Offer your services to funds and investors willing to explore opportunities in Italy. Become a partner!

by Partner
June 6, 2023

Sign up to our newsletter

SIGN UP

Related Posts

DACH

Vienna-based Optimuse raises €4 million seed round to scale AI-driven building engineering

October 1, 2025
UK&IRELAND

Irish BioTech Aerska launches with €17 million to develop RNAi medicines for diseases of the brain

October 1, 2025
FRANCE

Ecobat Completes Sale of French Lead Operations to Campine

October 1, 2025

ItaHub

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

Crypto-assets supervision rules in Italy, Banca d’Italia will supervise payment systems and Consob on market abuse

November 4, 2024
Italy’s SMEs export toward 260 bn euros in 2025

Italy’s SMEs export toward 260 bn euros in 2025

September 9, 2024
With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

With two months to go before the NPL Directive, in Italy the securitization rebus is still to be unraveled

April 23, 2024
EU’s AI Act, like previous rules on technology,  looks more defensive than investment-oriented

EU’s AI Act, like previous rules on technology, looks more defensive than investment-oriented

January 9, 2024

Co-sponsor

Premium

Italian private equity accelerates, driven by add-ons. BeBeez reports.

Italian private equity accelerates, driven by add-ons. BeBeez reports.

September 7, 2025
AlixPartners: Automotive, retail and manufacturing sectors may go through restructuring in 2025

AlixPartners: Automotive, retail and manufacturing sectors may go through restructuring in 2025

July 11, 2025
Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

Funds vying for management consulting firm BIP, a CVC portfolio company. All deals in the sector

March 6, 2025
Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

Private equity, Italy 2024 closes with 588 deals as for investments and divestments from 549 in 2023. Here is the new BeBeez’s report

February 10, 2025
Next Post

Vienna-based Optimuse raises €4 million seed round to scale AI-driven building engineering

EdiBeez srl

C.so Italia 22 - 20122 - Milano
C.F. | P.IVA 09375120962
Aut. Trib. Milano n. 102
del 3 aprile 2013

COUNTRY

Italy
Iberia
France
UK&Ireland
Benelux
DACH
Scandinavia&Baltics

CATEGORY

Private Equity
Venture Capital
Private Debt
Distressed Assets
Real Estate
Fintech
Green

PREMIUM

ItaHUB
Legal
Tax
Trend
Report
Insight view

WHO WE ARE

About Us
Media Partnerships
Contact

INFORMATION

Privacy Policy
Terms&Conditions
Cookie Police

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • COUNTRY
    • ITALY
    • IBERIA
    • FRANCE
    • UK&IRELAND
    • BENELUX
    • DACH
    • SCANDINAVIA&BALTICS
  • PRIVATE EQUITY
  • VENTURE CAPITAL
  • PRIVATE DEBT
  • DISTRESSED ASSETS
  • REAL ESTATE
  • FINTECH
  • GREEN
  • PREMIUM
    • ItaHub
      • ItaHub Legal
      • ItaHub Tax
      • ItaHub Trend
    • REPORT
    • INSIGHT VIEW
    • Private Data
Subscribe
  • Login
  • Cart